Helix BioPharma Corp. Reports on Advancement of Its L-DOS47

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Helix BioPharma Corp. Reports on Advancement of Its L-DOS47 Phase I/II Study in Poland

AURORA, ON--(Marketwired - Mar 8, 2016) - Helix BioPharma Corp. ( TSX : HBP ) ( FRANKFURT : HBP ), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Registration Office of Medicinal Products, Medical Devices and Biocides in Poland and the Bioethics Committee has approved an amendment to the Phase I/II study ("LDOS002") defining the dose and dosing regimen for the Phase II study.

The following changes were approved and will be implemented once the Phase II dose has been determined:

  • There will be no further escalations of L-DOS47 past cohort 16. If there are no further dose limiting toxicities, the Cohort 16 dose, 13.55 µg/kg, will be the dose administered to patients in the Phase II dose.
  • The safety profile supports a more frequent administration of L-DOS47. After reviewing safety, pharmacokinetic and immunogenicity data, L-DOS47 will be dosed twice weekly over 14 days (Days 1, 4, 8, 11) followed by a 7 day rest in the Phase II study.
  • The number of patients in the Phase II study will be increased to 45 patients. Based on Simon's optimal two-stage design, seventeen (17) evaluable patients will be enrolled in the first stage of the Phase II component of the study. If there is/are ≥ 1 response(s) out of these initial 17 evaluable patients, twenty-two (22) additional evaluable patients will need to be enrolled. To obtain 39 patients evaluable for response, enrolment of approximately 45 patients are needed.

The primary objective of the Phase II study is to make a preliminary assessment of efficacy of L-DOS47 in patients with non-squamous non-small cell lung cancer.

"The approval of the amendment to the Phase I/II study in Poland is very important news for the company," said Dr. Zbigniew Markowski, Helix Chief Executive Officer. "The Phase II component of the protocol is now optimally designed to provide a potential first efficacy signal for L-DOS47."

The company will be meeting with Investigators in April 2016 to discuss these changes and will be launching the Phase II study following a review of Phase I data from the Trial Steering Committee.

About L-DOS47

L-DOS47 is Helix's first immunoconjugate based drug candidate in development based on the Company's novel DOS47 platform technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction.

About L-DOS47 clinical development

L-DOS47 is currently being clinically evaluated in two clinical studies, in Poland and in the United States, as a treatment for certain patients with non-small cell lung cancer ("NSCLC").

LDOS002 is an open-label Phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of ascending doses of L-DOS47, initially as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb/IV NSCLC. The study is being conducted at five Polish centers under the direction of Dr. Dariusz Kowalski at The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology as the overall coordinating investigator, together with four other principal investigators: Prof. Cezary Szczylik, MD, PhD at the Military Medical Institute, Prof. Elzbieta Wiatr, MD, PhD at the National Tuberculosis and Lung Diseases Research Institute, Dr. Aleksandra Szczensa, MD, PhD at the Mazovian Center of Pulmonary Diseases and Tuberculosis in Otwock and Prof. Rodryg Ramlau, MD, PhD at the Department of Oncology, Poznan University of Medical Science.

LDOS001 is a Phase I, open-label, dose escalation study being conducted in the United States at three centers: The University of Texas, M.D. Anderson Cancer Centre, Penn State Milton S. Hershey Medical Center; and University Hospitals Case Medical Center. The primary objective of the study is to determine the safety and tolerability of L-DOS47 in combination treatment with pemetrexed/carboplatin. The study will also evaluate the potential clinical benefit of L-DOS47 with this combination. Other exploratory objectives include the evaluation of the L-DOS47 pharmacokinetics and immunogenicity.

Forward-Looking Statements and Risks and Uncertainties

This news release contains certain forward-looking statements and information (collectively, "forward- looking statements") within the meaning of applicable Canadian securities laws, including, without limitation, those relating to the total number of patients that will be enrolled in the Polish Phase I/II clinical study, the intention of the Company not to enrol patients in the Phase I portion of LDOS002 beyond Cohort 16, the intention to commence Phase II of LDOS002 following MTD being observed or the reaching of Cohort 16, whichever occurs first, which may be identified by words including, without limitation, "will", "intend", "planning" and other similar expressions, are intended to provide information about management's current plans and expectations regarding the conduct of the clinical study and the other operations of Helix.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, (i) the inherent uncertainty involved in scientific research and drug development; (ii) the risks associated with delay or inability to complete clinical trials successfully, including that patient recruitment for the Polish Phase I/II clinical trial for L-DOS47 does not continue as scheduled or at all, and the long lead-times and high costs associated with obtaining regulatory approval to market any product which may result from successful completion of such trials; (iii) need to secure additional financing on terms satisfactory to Helix or at all; (iv) clinical trials that yield negative results, or results that do not justify future clinical development, including that the Polish Phase I/II clinical trial for L-DOS47 will yield negative results; and (v) those risks and uncertainties affecting the company as more fully described in Helix's most recent Annual Report, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com  (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.

Investor Relations: Helix BioPharma Corp. 3-305 Industrial Parkway South Aurora, Ontario, L4G 6X7 Tel: 905 841-2300 Fax: (905) 841-2244 Email: ir@helixbiopharma.com Web: www.helixbiopharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 254

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 72

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 72

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 135

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 69

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 95

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 34

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 93

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 46

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
AutoMobility LA Puts 2028 Mobility on Center Stage

Updated Category News Views 38

Los Angeles is cramming an awful lot of automotive ambition into one Thursday. AutoMobility LA opens November 19 at the Los Angeles Convention Center, one day before the LA Auto Show begins its November 20–29 public run. Yes, there will be coffee carts, awards, creators and the usual event confetti. But beneath that polished show-floor racket sits a fairly serious...

Continue Reading

Top 5 Most Recently Viewed Articles

Easterly ROCMuni Bond Fund Faces Investigation for Misconduct

Updated Category News Views 327

Investigation of Easterly ROCMuni High Income Bond Fund Investors of the Easterly ROCMuni High Income Municipal Bond Fund are facing troubling times. Recently, the Portnoy Law Firm initiated an investigation regarding potential securities fraud associated with this investment vehicle. If you have lost money after investing in the Easterly ROCMuni High Income, it's...

Continue Reading
Japan's Economic Transformation: Unleashing Investment Potential

Updated Category News Views 271

Understanding the Shift in Japanese Equities Japanese equities are experiencing a resurgence, and this transformation is hard to ignore. The landscape of investment in Japan is shifting rapidly, and for those keeping an eye on the developments, there are compelling reasons to be optimistic. For years, conventional thought had deemed Japan as a country facing overwhelming...

Continue Reading
Pet Grooming Services Market Growth Driven by Humanization Trends

Updated Category News Views 129

Exploring the Pet Grooming Services Market Growth The pet grooming services market is witnessing a remarkable transformation, with anticipated growth projected to reach over USD 12.05 billion during the next decade. The rising phenomenon of pet ownership, coupled with the ongoing trend of humanization, is significantly influencing this expansion. The global market was...

Continue Reading
Investors Unite Against Dow Inc. in Class Action Suit

Updated Category News Views 181

Class Action Lawsuit Filed Against Dow Inc. Pomerantz LLP has announced the filing of a significant class action lawsuit against Dow Inc. (NYSE: DOW) and certain high-ranking officials within the company. This legal move signals a definitive call to action for investors who may have been adversely affected by the company’s alleged misrepresentations and omissions...

Continue Reading
Innovative Philanthropy: A New Challenge for MrBeast

Updated Category News Views 505

Revolutionizing Philanthropy: A New Challenge for MrBeast In an exciting initiative that aims to transform the landscape of modern philanthropy, the 144K Collective has reached out to the well-known YouTube personality and philanthropy leader Jimmy Donaldson, popularly known as MrBeast. This event, titled "144K Vs. The Beast," represents a novel approach to enhancing...

Continue Reading